San Diego-based NeuroGenetic Pharmaceuticals Inc. said Wednesday the Food and Drug Administration has approved clinical trials of its NGP 555 compound to treat and prevent Alzheimer’s disease. The approval follows successful pre-clinical toxicology and safety studies of the drug under federal grants totaling $3.4 million. “NGP 555 prevented the formation of and the deposition of amyloid plaques, […]